Global Dendritic Cell Cancer Vaccine Market Outlook 2020
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community which only eased out with the further ongoing clinical trials.
However, gone are the gloomy days for the dendritic cells, the sentinels of the immune system, as its market share in cancer market is rising exponentially. Dendritic cell cancer vaccines which started its journey with ex-vivo clinical trials in murine models have now gone on to rephrasing the molecular mechanism of the immune system, enriching our immunological knowledge and empowering our ability to counteract the tumor growth. Dendritic cells have also been successful in generating therapeutic and prophylactic options not just for cancer treatments but also for other ailments, deemed incurable.
Dendritic cells play a critical role in immune modulation, which makes them a perfect target for the clinical studies revolving around T cell induced immune reaction like allergic reaction studies, host v/s graft disease, infection resistance studies and immune-compromised patient studies, besides cancer vaccines development. However, it has been seen that many tumor antigens do not induce T cell mediated immune response which could be due the absence of functional dendritic cells in the tumors. It has been observed that dendritic cells that invade colon and skin cancer cells, sometimes lack CD80 and CD86 epitopes, therefore have limited T-cell stimulatory activity. Besides, tumors are capable of secreting growth factors like interleukin-10, Tumor Growth Factor, which retards the development and the maturation stages of dendritic cells. This implies that with increased dendritic cells invading the tumor cells the probability of enhanced prognosis is greatly increased.
There are several combinational therapies wherein dendritic cells are administered along with monoclonal antibodies, antibody-drug conjugates and peptide based vaccines to increase the efficacy of the vaccines. This is because of the fact that in the cancer patients, the immune system is already compromised, besides the tumor microenvironment which negates the mechanism of action of immunological cells. The role of conventional therapy like chemotherapy, surgical removal of tumor cells or radiotherapy also needs to be underscored as they help in reducing the bulk of tumorous growth. The cancer based vaccines when administered thereafter, is reported to have increased efficiency.
As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion’s share on cancer vaccine market.
“Global Dendritic Cell Cancer Vaccine Market Outlook 2020” Report highlights:
Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community which only eased out with the further ongoing clinical trials.
However, gone are the gloomy days for the dendritic cells, the sentinels of the immune system, as its market share in cancer market is rising exponentially. Dendritic cell cancer vaccines which started its journey with ex-vivo clinical trials in murine models have now gone on to rephrasing the molecular mechanism of the immune system, enriching our immunological knowledge and empowering our ability to counteract the tumor growth. Dendritic cells have also been successful in generating therapeutic and prophylactic options not just for cancer treatments but also for other ailments, deemed incurable.
Dendritic cells play a critical role in immune modulation, which makes them a perfect target for the clinical studies revolving around T cell induced immune reaction like allergic reaction studies, host v/s graft disease, infection resistance studies and immune-compromised patient studies, besides cancer vaccines development. However, it has been seen that many tumor antigens do not induce T cell mediated immune response which could be due the absence of functional dendritic cells in the tumors. It has been observed that dendritic cells that invade colon and skin cancer cells, sometimes lack CD80 and CD86 epitopes, therefore have limited T-cell stimulatory activity. Besides, tumors are capable of secreting growth factors like interleukin-10, Tumor Growth Factor, which retards the development and the maturation stages of dendritic cells. This implies that with increased dendritic cells invading the tumor cells the probability of enhanced prognosis is greatly increased.
There are several combinational therapies wherein dendritic cells are administered along with monoclonal antibodies, antibody-drug conjugates and peptide based vaccines to increase the efficacy of the vaccines. This is because of the fact that in the cancer patients, the immune system is already compromised, besides the tumor microenvironment which negates the mechanism of action of immunological cells. The role of conventional therapy like chemotherapy, surgical removal of tumor cells or radiotherapy also needs to be underscored as they help in reducing the bulk of tumorous growth. The cancer based vaccines when administered thereafter, is reported to have increased efficiency.
As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion’s share on cancer vaccine market.
“Global Dendritic Cell Cancer Vaccine Market Outlook 2020” Report highlights:
- Introduction & Mechanism of Action of Dendritic Cells
- New Vaccine Strategies That Exploit Dendritic Cells Biochemistry
- Dendritic Cell Cancer Vaccine Market & Clinical Insight
- Comparative Insight of Dendritic Cell Vaccines & Other Class of Vaccines
- Dendritic Cell Cancer Vaccine Pipeline by Country, Company, Indication & Phase
- Dendritic Cell Cancer Vaccine Clinical Pipeline: 58 Vaccines
- Majority in Phase I/II & Phase II Clinical Trials: 12 Vaccines
1. DENDRITIC CELLS CANCER VACCINE: THE GENESIS
2. CLASSIFICATION OF DENDRITIC CELLS
3. MECHANISM OF ACTION OF DENDRITIC CELLS
3.1 Antigen Presentation & Induction of Cellular Immune Responses
3.2 Sources of Antigen to Be Loaded Onto Dendritic Cells
3.3 Dendritic Cells Source & Subsets
3.4 Maturational State
3.5 Maturation Stimuli
3.6 Migration
3.7 Route, Dose & Schedule of Dendritic Cells Vaccination
3.8 Clinical Results in Miscellaneous Cancers
3.9 Quality Control
3.10 Immune Monitoring
4. NEW VACCINE STRATEGIES THAT EXPLOIT DENDRITIC CELLS BIOCHEMISTRY
4.1 Provision of CD4 T-Cell Help for CD8 T Cells
4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
4.3 Strategies to Activate NKT Cells
5. DENDRITIC CELL CANCER VACCINE MARKET & CLINICAL INSIGHT
5.1 Some Trends Involving Dendritic Cells Cancer Vaccination
5.2 Dendritic Cell Cancer Vaccine Pipeline Overview
6. A COMPARATIVE INSIGHT OF DENDRITIC CELL VACCINES & ITS PEERS
6.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
6.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
6.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
6.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine
7. THE GROWTH FACTORS: WHY THE FIXATION WITH DENDRITIC CELL CANCER VACCINES?
8. ROAD AHEAD: DENDRITIC CELL CANCER VACCINE IN THE CHALLENGING HORIZON OF CANCER IMMUNOTHERAPY
9. CONCLUSION: DENDRITIC CELL CANCER VACCINE; A SILVER LINING TO THE DARK UNDER-BELLY OF CANCER
10. DENDRITIC CELL CANCER VACCINE CLINICAL PIPELINE BY COUNTRY, COMPANY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase-I
10.5 Phase-I/II
10.6 Phase-II
10.7 Phase-II/III
10.8 Phase-III
11. MARKETED DENDRITIC CELL CANCER VACCINE: CREAVAX® ( RENAL CANCER, SOUTH KOREA)
12. MARKET WITHDRAWL: PROVENGE BY DENDREON CORPORATION
13. DISCONTINUED & SUSPENDED DENDRITIC CELL CANCER VACCINE IN CLINICAL TRIALS
13.1 Discontinued
13.2 No Development Reported
13.3 Suspended
14. COMPETITVE LANDSCAPE
14.1 3M Company
14.2 Activartis
14.3 Argos Therapeutics
14.4 Batavia Bioservices
14.5 Bellicum Pharmaceuticals
14.6 Creagene
14.7 DanDrit Biotech
14.8 DCPrime
14.9 Dendreon Corporation
14.10 Elios Therapeutics
14.11 ImmunoCellular Therapeutics
14.12 Immunicum
14.13 Kiromic
14.14 Medigene
14.15 Merck
14.16 Northwest Biotherapeutics
14.17 Glaxo Smith Kline
14.18 ImmunoCellular Therapeutics
14.19 SOTIO
14.20 Tella Incorporation
14.21 Theravectys
14.22 Vaxil BioTherapeutics
2. CLASSIFICATION OF DENDRITIC CELLS
3. MECHANISM OF ACTION OF DENDRITIC CELLS
3.1 Antigen Presentation & Induction of Cellular Immune Responses
3.2 Sources of Antigen to Be Loaded Onto Dendritic Cells
3.3 Dendritic Cells Source & Subsets
3.4 Maturational State
3.5 Maturation Stimuli
3.6 Migration
3.7 Route, Dose & Schedule of Dendritic Cells Vaccination
3.8 Clinical Results in Miscellaneous Cancers
3.9 Quality Control
3.10 Immune Monitoring
4. NEW VACCINE STRATEGIES THAT EXPLOIT DENDRITIC CELLS BIOCHEMISTRY
4.1 Provision of CD4 T-Cell Help for CD8 T Cells
4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
4.3 Strategies to Activate NKT Cells
5. DENDRITIC CELL CANCER VACCINE MARKET & CLINICAL INSIGHT
5.1 Some Trends Involving Dendritic Cells Cancer Vaccination
5.2 Dendritic Cell Cancer Vaccine Pipeline Overview
6. A COMPARATIVE INSIGHT OF DENDRITIC CELL VACCINES & ITS PEERS
6.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
6.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
6.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
6.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine
7. THE GROWTH FACTORS: WHY THE FIXATION WITH DENDRITIC CELL CANCER VACCINES?
8. ROAD AHEAD: DENDRITIC CELL CANCER VACCINE IN THE CHALLENGING HORIZON OF CANCER IMMUNOTHERAPY
9. CONCLUSION: DENDRITIC CELL CANCER VACCINE; A SILVER LINING TO THE DARK UNDER-BELLY OF CANCER
10. DENDRITIC CELL CANCER VACCINE CLINICAL PIPELINE BY COUNTRY, COMPANY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase-I
10.5 Phase-I/II
10.6 Phase-II
10.7 Phase-II/III
10.8 Phase-III
11. MARKETED DENDRITIC CELL CANCER VACCINE: CREAVAX® ( RENAL CANCER, SOUTH KOREA)
12. MARKET WITHDRAWL: PROVENGE BY DENDREON CORPORATION
13. DISCONTINUED & SUSPENDED DENDRITIC CELL CANCER VACCINE IN CLINICAL TRIALS
13.1 Discontinued
13.2 No Development Reported
13.3 Suspended
14. COMPETITVE LANDSCAPE
14.1 3M Company
14.2 Activartis
14.3 Argos Therapeutics
14.4 Batavia Bioservices
14.5 Bellicum Pharmaceuticals
14.6 Creagene
14.7 DanDrit Biotech
14.8 DCPrime
14.9 Dendreon Corporation
14.10 Elios Therapeutics
14.11 ImmunoCellular Therapeutics
14.12 Immunicum
14.13 Kiromic
14.14 Medigene
14.15 Merck
14.16 Northwest Biotherapeutics
14.17 Glaxo Smith Kline
14.18 ImmunoCellular Therapeutics
14.19 SOTIO
14.20 Tella Incorporation
14.21 Theravectys
14.22 Vaxil BioTherapeutics
LIST OF FIGURES
Figure 1-1: Advantages of Dendritic Cell Cancer Vaccine
Figure 2-1: Classification of Dendritic Cells
Figure 3-1: Principle of Dendritic Cell Cancer Immunotherapy
Figure 3-2: The Key Players Intricately Involved in Antigen Presentation & Immune Response Machinery
Figure 3-3: Process of Antigen-loading
Figure 3-4: Major Life Cycle Events of a Dendritic Cell
Figure 3-5: A Diagrammatic Representation of Dendritic Cell Plasticity
Figure 3-6: Action of Dendritic Cells on the Various Cancer Forms
Figure 4-1: The Arsenals in the Inventory of Dendritic Cells
Figure 5-1: Recent Trends in Dendritic Cell Vaccine
Figure 5-2: Dendritic Cell Cancer Vaccine by Phase (%), 2016
Figure 5-3: Dendritic Cell Cancer Vaccine by Phase (Numbers), 2016
Figure 6-1: Working Principle Targeted By Dendritic Cells & Monoclonal Antibodies
Figure 6-2: Working Principle Targeted by Dendritic Cells & Peptide Cancer Vaccines
Figure 6-3: Working Principle Targeted by Dendritic Cells & Cytokine Cancer Vaccine
Figure 6-4: Working Principle Targeted By Dendritic Cells & Antibody-Drug Conjugates Cancer Vaccines
Figure 7-1: Factors Driving Dendritic Cell Cancer Vaccine
Figure 8-1: Challenges for Dendritic Cell Cancer Vaccine
Figure 14-1: Argos Therapeutics- Clinical Pipeline
Figure 14-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 14-3: DCPrime Clinical Pipeline
Figure 14-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 14-5: Immunicum Clinical Pipeline
Figure 14-6: Medigene Clinical Pipeline
Figure 14-7: Northwest Biotherapeutics Clinical Pipeline
Figure 14-8: SOTIO Clinical Pipeline
Figure 1-1: Advantages of Dendritic Cell Cancer Vaccine
Figure 2-1: Classification of Dendritic Cells
Figure 3-1: Principle of Dendritic Cell Cancer Immunotherapy
Figure 3-2: The Key Players Intricately Involved in Antigen Presentation & Immune Response Machinery
Figure 3-3: Process of Antigen-loading
Figure 3-4: Major Life Cycle Events of a Dendritic Cell
Figure 3-5: A Diagrammatic Representation of Dendritic Cell Plasticity
Figure 3-6: Action of Dendritic Cells on the Various Cancer Forms
Figure 4-1: The Arsenals in the Inventory of Dendritic Cells
Figure 5-1: Recent Trends in Dendritic Cell Vaccine
Figure 5-2: Dendritic Cell Cancer Vaccine by Phase (%), 2016
Figure 5-3: Dendritic Cell Cancer Vaccine by Phase (Numbers), 2016
Figure 6-1: Working Principle Targeted By Dendritic Cells & Monoclonal Antibodies
Figure 6-2: Working Principle Targeted by Dendritic Cells & Peptide Cancer Vaccines
Figure 6-3: Working Principle Targeted by Dendritic Cells & Cytokine Cancer Vaccine
Figure 6-4: Working Principle Targeted By Dendritic Cells & Antibody-Drug Conjugates Cancer Vaccines
Figure 7-1: Factors Driving Dendritic Cell Cancer Vaccine
Figure 8-1: Challenges for Dendritic Cell Cancer Vaccine
Figure 14-1: Argos Therapeutics- Clinical Pipeline
Figure 14-2: Bellicum Pharmaceuticals Clinical Pipeline
Figure 14-3: DCPrime Clinical Pipeline
Figure 14-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 14-5: Immunicum Clinical Pipeline
Figure 14-6: Medigene Clinical Pipeline
Figure 14-7: Northwest Biotherapeutics Clinical Pipeline
Figure 14-8: SOTIO Clinical Pipeline
